A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-controlled (ustekinumab), double-blind within dose groups of BI 655066)
Latest Information Update: 13 Jan 2022
At a glance
- Drugs Risankizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 31 Oct 2019 Results published in the Clinical Pharmacokinetics
- 04 May 2019 Results assessing comprehensive analysis of risankizumab pharmacokinetics in healthy subjects and patients with plaque psoriasis using data across phase I-III clinical trials (NCT01577550, NCT02054481, NCT02596217, NCT02684370, NCT02672852, NCT02684357, NCT02694523) published in the Clinical Pharmacokinetics.
- 16 Mar 2019 Results characterizing the population pharmacokinetics (PK) of RZB in patients with moderate to severe chronic plaque psoriasis using phase III trial data presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics